MedTrace Logo

Study to Assess the Efficacy of the iTind in Subjects With Symptomatic BPH

NCT03395522 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 149

Last updated 2023-10-23

No results posted yet for this study

Summary

A total of up to 200 Symptomatic BPH subjects subjects will be enrolled into the study.

Study duration will be 12 months post implantation with a follow-up visits at Year 2 and Year 3.

Conditions

  • BPH

Interventions

DEVICE

iTind

device implanted for 5-7 days

Sponsors & Collaborators

  • Medi-Tate Ltd.

    lead INDUSTRY

Principal Investigators

  • Francesco Porpiglia, MD · San Orbessano

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-02-18
Primary Completion
2023-06-18
Completion
2025-04-25

Countries

  • Australia
  • France
  • Germany
  • Italy
  • Spain
  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03395522 on ClinicalTrials.gov